on PharmaSGP Holding SE (isin : DE000A2P4LJ5)
PharmaSGP Reports Revenue and EBITDA Growth in 2024
PharmaSGP Holding SE, a German OTC pharmaceutical company, announced a significant increase in its 2024 revenues and EBITDA. Revenues rose by 17.5% to €118.8 million, attributed entirely to organic growth. Adjusted EBITDA increased by 9.2% to €37.2 million, with a margin of 31.3%.
CEO Peter Gerckens emphasized the success of PharmaSGP’s platform strategy in achieving this growth. The company continues to focus on organic portfolio expansion and efficient product launches. CFO Michael Rudolf highlighted strong market performance and plans for further product launches and M&A opportunities in 2025.
PharmaSGP forecasts 2025 revenues between €122.0 million and €128.0 million, with an EBITDA of €37.0 million to €39.0 million, despite geopolitical uncertainties. The full 2024 annual report will be released on April 30, 2025.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PharmaSGP Holding SE news